Vertical Pharmaceuticals LLC, an Osmotica company, Announces Presentation of Phase III RVL-1201 Clinical Trial Data in Patients with Acquired Blepharoptosis (droopy eyelid)
(World News Science)

BRIDGEWATER, N.J., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Vertical Pharmaceuticals, LLC (a subsidiary of Osmotica Pharmaceuticals plc (`Osmotica` or the `Company`) (Nasdaq: OSMT), a fully integrated biopharmaceutical company) today announced that Phase III clinical trial results for RVL-1201 (oxymetazoline hydrochloride ophthalmic solution, 0.1%) will be presented at multiple global congresses in October and November. `With the New Drug Application (NDA) now submitted for RVL-1201, we are excited to have the opportunity to present these data and build upon the scientific and medical awareness of RVL-1201 and acquired blepharoptosis,` said Brian Markison, Osmotica`s Chief Executive Officer. Phase...